Together with MRBB and Other Stable Shareholders, Cera and KBC Ancora have confirmed to extend their anchoring agreement with respect to KBC Group NV for a further term of ten years. In doing so, ...
Cera and KBC Ancora, together with MRBB and the other stable shareholders, confirmed on 29 November 2024 they would be extending unchanged their anchoring agreement with respect to KBC Group for a ...
On June 28, 2024, the FDA approved three new biosimilars, Formycon and Klinge Biopharma’s Ahzantive® (aflibercept-mrbb), a biosimilar of Regeneron’s ...
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of ...
Cera and KBC Ancora extend their KBC Group 'anchoring agreements' Together with MRBB and the Other Stable Shareholders, Cera and KBC Ancora ensure the shareholder stability and further development of ...
Comparable efficacy between the biosimilar and reference product was demonstrated in the phase 3 MAGELLAN-AMD study. The Food and Drug Administration (FDA) has approved Ahzantive ® (aflibercept-mrbb), ...
Together with MRBB and Other Stable Shareholders, Cera and KBC Ancora have confirmed to extend their anchoring agreement with respect to KBC Group NV for a further term of ten years. In doing so, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results